Research graph
References from Hypothyroidism in patients treated with immune checkpoint inhibitors. Local targets link to admitted publications; unresolved targets remain external evidence.
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study
10.1007/s40618-023-02268-0 · 2024 · External reference
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: A prospective study from a single tertiary center
10.1530/erc-24-0101 · 2024 · External reference
Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis
10.1001/jamaoncol.2017.3064 · 2018 · External reference
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: A systematic review and meta-analysis
10.1007/s00262-021-03128-7 · 2022 · External reference
Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction
10.1111/1759-7714.13347 · 2020 · External reference
Immune checkpoint inhibitors-induced endocrinopathies: Assessment, management and monitoring in a comprehensive cancer centre
10.1002/edm2.505 · 2024 · External reference
Increased thyroidal activity on routine FDG-PET/CT after combination immune checkpoint inhibition: Temporal associations with clinical and biochemical thyroiditis
10.3390/cancers15245803 · 2023 · External reference
Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.001 · 2022 · External reference
Thyroid disorders in the oncology patient
2015 · External reference
A comprehensive review of immune checkpoint inhibitors for cancer treatment
2024 · External reference
Sex: A potential factor affecting immune checkpoint inhibitor therapy for cancers
10.3389/fimmu.2022.1024112 · 2022 · External reference
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An ESE clinical practice guideline
10.1530/eje-22-0689 · 2022 · External reference
Immune-related thyroiditis with immune checkpoint inhibitors
10.1089/thy.2018.0116 · 2018 · External reference
PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients
10.1089/thy.2019.0250 · 2020 · External reference
Clinical significance of thyroid autoantibodies in differential diagnosis and predicting the course of programmed cell death protein-1 inhibitor-induced thyroid dysfunction
10.1016/j.eprac.2024.08.012 · 2024 · External reference
Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
10.3389/fendo.2025.1584675 · 2025 · External reference
Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization
10.1080/21645515.2024.2410557 · 2024 · External reference
The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC
10.1080/1750743x.2024.2394382 · 2024 · External reference
CTLA-4: A moving target in immunotherapy
10.1182/blood-2017-06-741033 · 2018 · External reference
Clinical determinants and outcomes of hypothyroidism in immune checkpoint inhibitor (ICI) therapy
2025 · External reference
A decrease in peripheral thyroid hormone conversion efficiency in patients treated with immune checkpoint inhibitors and L-T3 as a possible alternative therapeutic escape option
10.1111/eci.13790 · 2022 · External reference
Levothyroxine interactions with food and dietary supplements: A systematic review
10.3390/ph14030206 · 2021 · External reference
Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy
10.1371/journal.pone.0156925 · 2016 · External reference
Unresolved reference
External reference
Clinical features of nivolumab-induced thyroiditis: A case series study
10.1089/thy.2016.0562 · 2017 · External reference
Association between body mass index and immune-related adverse events (irAEs) among advanced-stage cancer patients receiving immune checkpoint inhibitors: A pan-cancer analysis
10.3390/cancers13236109 · 2021 · External reference
Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis
10.1001/jamaoncol.2017.3064 · ExternalCitation · doi-reference
Immune checkpoint inhibitors-induced endocrinopathies: Assessment, management and monitoring in a comprehensive cancer centre
10.1002/edm2.505 · ExternalCitation · doi-reference
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: A systematic review and meta-analysis
10.1007/s00262-021-03128-7 · ExternalCitation · doi-reference
Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study
10.1007/s40618-023-02268-0 · ExternalCitation · doi-reference
Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.10.001 · ExternalCitation · doi-reference
Clinical significance of thyroid autoantibodies in differential diagnosis and predicting the course of programmed cell death protein-1 inhibitor-induced thyroid dysfunction
10.1016/j.eprac.2024.08.012 · ExternalCitation · doi-reference
The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC
10.1080/1750743x.2024.2394382 · ExternalCitation · doi-reference
Exploring risk factors for endocrine-related immune-related adverse events: Insights from meta-analysis and Mendelian randomization
10.1080/21645515.2024.2410557 · ExternalCitation · doi-reference
Clinical features of nivolumab-induced thyroiditis: A case series study
10.1089/thy.2016.0562 · ExternalCitation · doi-reference
Immune-related thyroiditis with immune checkpoint inhibitors
10.1089/thy.2018.0116 · ExternalCitation · doi-reference
PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients
10.1089/thy.2019.0250 · ExternalCitation · doi-reference
Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction
10.1111/1759-7714.13347 · ExternalCitation · doi-reference
A decrease in peripheral thyroid hormone conversion efficiency in patients treated with immune checkpoint inhibitors and L-T3 as a possible alternative therapeutic escape option
10.1111/eci.13790 · ExternalCitation · doi-reference
CTLA-4: A moving target in immunotherapy
10.1182/blood-2017-06-741033 · ExternalCitation · doi-reference
Disease-specific as well as generic quality of life is widely impacted in autoimmune hypothyroidism and improves during the first six months of levothyroxine therapy
10.1371/journal.pone.0156925 · ExternalCitation · doi-reference
Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An ESE clinical practice guideline
10.1530/eje-22-0689 · ExternalCitation · doi-reference
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: A prospective study from a single tertiary center
10.1530/erc-24-0101 · ExternalCitation · doi-reference
Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
10.3389/fendo.2025.1584675 · ExternalCitation · doi-reference
Sex: A potential factor affecting immune checkpoint inhibitor therapy for cancers
10.3389/fimmu.2022.1024112 · ExternalCitation · doi-reference
Association between body mass index and immune-related adverse events (irAEs) among advanced-stage cancer patients receiving immune checkpoint inhibitors: A pan-cancer analysis
10.3390/cancers13236109 · ExternalCitation · doi-reference
Increased thyroidal activity on routine FDG-PET/CT after combination immune checkpoint inhibition: Temporal associations with clinical and biochemical thyroiditis
10.3390/cancers15245803 · ExternalCitation · doi-reference
Levothyroxine interactions with food and dietary supplements: A systematic review
10.3390/ph14030206 · ExternalCitation · doi-reference
